All News

The FDA staff report questioned the unusually poor performance of the control group used in the study.

The Senate introduced legislation this week that would require Medicare to consider patients' finances when deciding whether to punish a hospital for readmission numbers.

Virginia Gov. Terry McAuliffe vowed Friday to bypass the General Assembly and expand Medicaid eligibility for about 400,000 low-income residents on his own.

I'll say it: I think most states, if not all, will be on the Federal exchange by the end of the decade.

With just two weeks under her belt, Health and Human Services (HHS) Secretary Sylvia Mathews Burwell announced a series of changes that will be made to the federal health insurance marketplace following the enrollment and technological problems that ensued the launch of healthcare.gov earlier this year.

Newly diagnosed multiple myeloma patients undergoing ASCT showed a significant improvement in survival.

The US FDA has warned that intravenous administration docetaxal formulations contain alcohol and may cause intoxication among patients. A product label revision is being made.

A panel asks: "Due to the ACA, who is now presenting with cancer? Who is walking through the door and is there a difference between patients since the ACA implementation?"

Consumer advocacy group Public Citizen on Thursday called on 20 hospital systems to stop partnering with companies that offer low-cost screenings for heart disease and stroke risk, saying the promotions are "unethical" and the exams are more likely to do harm than good.

From 20 months to upto 5 years, blocking CD20 significantly improved OS in CLL patients.

For patients who survive cancer, annual medical costs can be nearly double those of non-cancer patients.

Twenty-two Democratic lawmakers have asked the National Institutes of Health to publicly disclose demographic data for all clinical trials posted on ClinicalTrials.gov.

The derivative slowed tumor growth, shrunk tumors, and extended the life of the mice.

BRCA2 mutation, a genetic risk factor for breast and ovarian cancer, has been implicated in squamous cell lung cancer among cigarette smokers.

Once strictly the domain of research labs, gene-sequencing tests increasingly are being used to help understand the genetic causes of rare disease, putting insurance companies in the position of deciding whether to pay the $5,000 to $17,000 for the tests.

The US healthcare system's shift from volume- to value-based reimbursement for treatment in order to lower costs and improve patient care is disrupting healthcare business models. The high-profile government—led accountable care organizations (ACOs), which put financial pressure on payers and providers to share responsibility for meeting quality and cost goals, is no exception.

As the bill for providing healthcare in the United States continues to grow, hospitals are finding that many of their expenses can be chalked up to patients with chronic illnesses such as diabetes and heart failure taking avoidable trips to the emergency room (ER).

Pfizer's deal with the French company will ensure a market share in the promising immunooncology field.

The oncolytic adenovirus vaccine, DNX-2401, being developed by DNAtrix to treat recurrent glioblastoma, has received a fast-track status by the FDA.

HHS is moving forward with its plan to allow certain hospitals to receive discounts on orphan drugs when they are used for non-orphan conditions despite a court ruling that said the agency did not have the authority to do so.

In community-based radiology practice, mammography screening with 3D digital breast tomosynthesis (DBT) yielded lower recall rates, an increased overall cancer detection rate, and an increased detection rate for invasive cancer compared with 2D digital mammography (DM).

Officials from HHS released new data detailing the profile of consumers who enrolled in federal health insurance exchange plans, and the data show that more than 8 million people signed up for coverage.

"Person-centered care" is the buzz phrase floating around the health care industry, and a Pacific Northwest-based giant insurer thinks it has hit the mark with a new palliative care program coming this summer.

Dr. Farzad Mostashari, former head of the Office of the National Coordinator for Health Information Technology, is starting a new firm, Aledade, to help independent primary-care physicians form accountable care organizations.

Icahn School of Medicine at Mount Sinai and Champions Oncology have initiated a study evaluating TumorGrafts' ability to predict treatment benefit in patients with triple-negative breast cancer. A side-by-side genomic analysis of patients' tumor and TumorGraft mouse avatars, before and after treatment, will also be conducted.

Despite reform and shifts in health policy, the United States healthcare system ranked last in quality compared with 10 other industrialized counties-just as it did in 2010, 2007, 2006, and 2004.

Two measures of the evolving health insurance market show that change is happening more quickly than anticipated.

Low-dose dexamethasone with pomalidomide improved overall survival to 12.7 months, compared to 5.7 months with high-dose dexamethasone.

A bold new way to test cancer drugs started Monday in hundreds of hospitals around the United States.

A proteomic test can predict outcome with chemotherapy versus erlotinib in NSCLC patients.